Stock Watch: Protocol Changes Preface Poor Trial Outcomes
Few If Any Changes To Clinical Trials Are Good
Executive Summary
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?
You may also be interested in...
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Stockwatch: Don't tell, hope no-one asks
The British legal system, respected and emulated around the world, is an adversarial one where the defence and the prosecution face off in a battle of words. I am starting to think that the battle for investors' money is also adversarial with the companies putting out statements that should be interrogated and challenged. When these statements aren't challenged, investors can become the collateral damage.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.